PH12018500859A1 - Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease - Google Patents
Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s diseaseInfo
- Publication number
- PH12018500859A1 PH12018500859A1 PH12018500859A PH12018500859A PH12018500859A1 PH 12018500859 A1 PH12018500859 A1 PH 12018500859A1 PH 12018500859 A PH12018500859 A PH 12018500859A PH 12018500859 A PH12018500859 A PH 12018500859A PH 12018500859 A1 PH12018500859 A1 PH 12018500859A1
- Authority
- PH
- Philippines
- Prior art keywords
- dihydroisoquinolin
- ethanone
- methylbutyl
- dichlorophenyl
- hydroxymethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245391P | 2015-10-23 | 2015-10-23 | |
PCT/US2016/057447 WO2017070068A1 (en) | 2015-10-23 | 2016-10-18 | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12018500859A1 true PH12018500859A1 (en) | 2018-10-29 |
Family
ID=57233858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12018500859A PH12018500859A1 (en) | 2015-10-23 | 2018-04-20 | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease |
Country Status (13)
Country | Link |
---|---|
CN (1) | CN108137506A (es) |
AR (1) | AR106332A1 (es) |
AU (1) | AU2016341115A1 (es) |
CA (1) | CA2999332A1 (es) |
DO (1) | DOP2018000103A (es) |
EA (1) | EA201890525A1 (es) |
EC (1) | ECSP18030976A (es) |
IL (1) | IL257872A (es) |
MX (1) | MX2018004794A (es) |
PE (1) | PE20181296A1 (es) |
PH (1) | PH12018500859A1 (es) |
TW (1) | TW201725199A (es) |
WO (1) | WO2017070068A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
JP2022514659A (ja) * | 2018-12-18 | 2022-02-14 | イーライ リリー アンド カンパニー | ドーパミン作動性cns障害の治療におけるly3154207の使用のための用量レジメン |
TWI825323B (zh) * | 2019-06-18 | 2023-12-11 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
WO2022192231A1 (en) | 2021-03-08 | 2022-09-15 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
EP4304577A1 (en) | 2021-03-09 | 2024-01-17 | Eli Lilly And Co. | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
CN113264926A (zh) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | 一种牡荆素与利血平的共晶及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
BRPI0808525A2 (pt) * | 2007-03-01 | 2014-08-19 | Janssen Pharmaceutica Nv | Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3 |
US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2016
- 2016-10-13 AR ARP160103122A patent/AR106332A1/es unknown
- 2016-10-14 TW TW105133203A patent/TW201725199A/zh unknown
- 2016-10-18 CA CA2999332A patent/CA2999332A1/en not_active Abandoned
- 2016-10-18 EA EA201890525A patent/EA201890525A1/ru unknown
- 2016-10-18 PE PE2018000570A patent/PE20181296A1/es not_active Application Discontinuation
- 2016-10-18 AU AU2016341115A patent/AU2016341115A1/en not_active Abandoned
- 2016-10-18 CN CN201680061907.6A patent/CN108137506A/zh active Pending
- 2016-10-18 MX MX2018004794A patent/MX2018004794A/es unknown
- 2016-10-18 WO PCT/US2016/057447 patent/WO2017070068A1/en active Application Filing
-
2018
- 2018-03-05 IL IL257872A patent/IL257872A/en unknown
- 2018-04-20 EC ECIEPI201830976A patent/ECSP18030976A/es unknown
- 2018-04-20 DO DO2018000103A patent/DOP2018000103A/es unknown
- 2018-04-20 PH PH12018500859A patent/PH12018500859A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201725199A (zh) | 2017-07-16 |
AR106332A1 (es) | 2018-01-03 |
CN108137506A (zh) | 2018-06-08 |
WO2017070068A1 (en) | 2017-04-27 |
DOP2018000103A (es) | 2018-10-31 |
CA2999332A1 (en) | 2017-04-27 |
AU2016341115A1 (en) | 2018-04-12 |
ECSP18030976A (es) | 2018-05-31 |
MX2018004794A (es) | 2018-06-19 |
IL257872A (en) | 2018-06-03 |
EA201890525A1 (ru) | 2018-09-28 |
PE20181296A1 (es) | 2018-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500859A1 (en) | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease | |
EP3638315A4 (en) | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
IL269599B1 (en) | 11, 13- modified schistosoxins for pain treatment | |
WO2015132799A3 (en) | Heterocyclic compounds | |
EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
IL285782A (en) | Compounds, compositions, and methods for treating disease | |
WO2015001504A3 (en) | Antibody formulations and methods | |
WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
MA44759B1 (fr) | Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide | |
EP3562514A4 (en) | GENE THERAPY TO TREAT WILSON'S DISEASE | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
WO2018067520A3 (en) | Therapeutic agents and methods: | |
NZ746468A (en) | Methods of treating ocular conditions | |
FI3609886T3 (fi) | Bentsoatsepiinianalogeja brutonin tyrosiinikinaasia estävinä aineina | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
TN2016000447A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands. | |
IL270927B (en) | fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases | |
EP3730144A4 (en) | AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | |
MA39450A1 (fr) | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine | |
EP3556366A4 (en) | USE OF CARBAMATE COMPOUNDS FOR THE PREVENTION, MITIGATION OR TREATMENT OF BIPOLAR DISORDER | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease |